Phaseline

Companies › SynAct Pharma Aps

SynAct Pharma Aps: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 2; Genitourinary, Immunology, Infectious disease; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AP1189
Toll-like receptor 7 (TLR7) agonist
–Phase 2Rheumatoid Arthritis (RA); Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy; Respiratory Viral InfectionAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06671054AP1189Phase 2Rheumatoid Arthritis (RA)ImmunologyDec 2025
NCT04456816AP1189Phase 2Nephrotic Syndrome Due to Idiopathic Membranous NephropathyGenitourinaryJun 2026
NCT07633288AP1189Phase 2Respiratory Viral InfectionInfectious diseaseAug 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

IR INNOVATE RESEARCH PRIVATE Shanghai Longwood Biopharmaceuticals Toll Biotech Co. Ltd. (Beijing) Ventus Therapeutics U.S. Hyundai Bioscience

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.